NYSE · STE
Healthcare · Medical - Devices
$253.44
Up+$10.88 (+4.29%)
Updated Nov 13, 2026, 10:46 PM
SID Score
6.4/10
Composite research score
Smart Money
58/100
Neutral
Price performance · STE
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 12, 2026
STE closed at $253.44 after 21 trading sessions, up 12.98% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 12, 2026 | $258.61 | $258.61 | $252.82 | $253.44 | 517.5K |
| Nov 11, 2026 | $253.45 | $257.14 | $252.085 | $256.27 | 596.64K |
| Nov 10, 2026 | $255.96 | $258.11 | $251.97 | $257.12 | 934.24K |
| Nov 9, 2026 | $253.59 | $259.09 | $249.67 | $256.94 | 1.13M |
| Nov 6, 2026 | $248.03 | $253.44 | $248.03 | $252.30 | 1.39M |
| Nov 5, 2026 | $252.35 | $259.245 | $247.675 | $254.12 | 1.65M |
| Nov 4, 2026 | $240.51 | $249.2825 | $236.77 | $247.91 | 1.38M |
| Nov 3, 2026 | $231.83 | $233.66 | $227.50 | $231.35 | 709.16K |
| Nov 2, 2026 | $229.33 | $233.75 | $228.23 | $233.35 | 617.47K |
| Oct 30, 2026 | $233.98 | $233.98 | $225.65 | $227.12 | 992.33K |
| Oct 29, 2026 | $231.18 | $232.46 | $229.21 | $232.14 | 485.78K |
| Oct 28, 2026 | $227.02 | $230.13 | $225.01 | $228.78 | 417.32K |
| Oct 27, 2026 | $229.42 | $230.37 | $227.06 | $228.49 | 459.47K |
| Oct 26, 2026 | $231.26 | $234.335 | $228.28 | $230.12 | 805.44K |
| Oct 23, 2026 | $230.79 | $233.14 | $229.39 | $232.15 | 564.66K |
| Oct 22, 2026 | $223.00 | $232.34 | $222.065 | $232.22 | 1.02M |
| Oct 21, 2026 | $222.77 | $226.24 | $221.00 | $221.48 | 1.79M |
| Oct 20, 2026 | $223.99 | $226.63 | $223.28 | $225.18 | 551.05K |
| Oct 19, 2026 | $220.34 | $223.41 | $219.80 | $221.97 | 477.4K |
| Oct 16, 2026 | $225.37 | $226.715 | $221.105 | $222.66 | 601.45K |
| Oct 15, 2026 | $221.81 | $224.51 | $219.00 | $224.33 | 838.58K |
The latest Smart Investors Daily articles mentioning STE.
Company
Market Activity
Research & News
STE research
Company profile and research snapshot.
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 6, 2026 | Keybanc | Overweight | — |
| Aug 7, 2026 | Piper Sandler | Overweight | — |
| Aug 7, 2026 | UBS | Buy | — |
| Jul 28, 2026 | UBS | Buy | — |
| May 13, 2026 | Keybanc | Overweight | — |
No generated briefing is available yet.
Yahoo · Nov 7, 2026
STERIS (NYSE:STE) raised its fiscal 2027 earnings outlook after reporting higher second-quarter revenue and profit, as tariff refunds helped expand margins and strong Life Sciences equipment shipments offset a slower start to the year in its sterilization business. Revenue rose 9% to $1.6 billion i
Yahoo · Nov 7, 2026
STERIS has delivered a 30.5% share price gain over the past three years, and with the stock recently closing at US$252.30, the live question is whether that move is fully supported by the cash the business is expected to generate. After a fresh set of results and an updated outlook, investors are weighing what the current price implies about the durability and timing of those cash flows. A 30.5% return over three years puts real weight on the assumption that STERIS can keep converting its...
Benzinga · Nov 6, 2026
Keybanc analyst Brett Fishbin maintains Steris (NYSE:STE) with a Overweight and raises the price target from $269 to $284.
Yahoo · Nov 6, 2026
Steris PLC (STE) delivered broad-based growth with record Life Sciences margins and a 19% EPS increase, while trimming its AST outlook and unveiling a new restructuring plan.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning STE.
